aod9604 clinical trials safety | Peptra Labs AOD-9604 (5mg) – Nordsci

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance

Although I could only find rat studies on PubMed, the peptide has generated excellent results in a Phase 2b clinical trial run by Metabolic Pharmaceuticals: The drug codenamed AOD9604 was taken orally once daily by 300 obese patients at five trial sites over a 12-week period

Thometz is a board-certified emergency medicine physician with over a decade of experience in high-volume emergency departments across the United States and internationally

This formulation is specifically designed to address conditions such as neuropathy, anemia, B12 deficiency, megaloblastic anemia, and Leber's disease

We say, YOU MATTER, because you are significant